EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Effectiveness of Ultrathin 40-Gauge Needles for Intravitreal Injections

Ye Ji Cho, Kyung Yun Kook, Do Hee Park, Yong-Sok Ji

Korean Journal of Ophthalmology · 05.08.2026 · 40 (4) · 341-347

DOI: 10.3341/kjo.2025.0134 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Korean Journal of Ophthalmology, erschienen am 05.08.2026. Verfasst von Ye Ji Cho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. Hauptthemen laut MEDLINE: Intravitreal Injections, Needles, Retinal Diseases. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare pain perception and immediate post‑procedural complications of intravitreal injections (IVIs) performed with conventional 30‑gauge needles versus ultrathin 40‑gauge needles.

Methods

This single-center, retrospective crossover study reviewed consecutive patients who underwent serial IVIs for neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, myopic choroidal neovascularization, or other indications between April and October 2020. Each patient received one injection with a 30‑gauge needle and one with a 40‑gauge needle—either to the fellow eye on the same day or to the same eye 1-month apart. Injections (0.05 mL bevacizumab, ranibizumab, or aflibercept) were administered in an operating room by a single surgeon following the guidelines of Avery et al. Pain was recorded immediately postinjection on a visual analog scale (VAS). Subconjunctival hemorrhage (SCH) and vitreous reflux (VR) were graded 0 to 4.

Results

Mean age was 69.3 ± 11.5 years; 69.0% were men. VAS pain scores were significantly lower with 40‑gauge needles than with 30‑gauge needles (2.33 ± 1.26 vs 4.02 ± 1.73; paired difference [mean ± standard error], −1.69 ± 0.33; p < 0.001). Median VR grade declined from 2 (interquartile range [IQR], 2–3) to 0 (IQR, 0–1) with 40‑gauge needles (p < 0.001). SCH grade did not differ between gauges (median [IQR], 0 [0–1]; p = 0.928). No injection-related adverse events occurred.

Conclusions

Using an ultrathin 40‑gauge needle for IVIs significantly reduces patient‑reported pain and VR without increasing subconjunctival hemorrhage. These findings support the integration of 40‑gauge needles into routine IVI practice to enhance long-term patient adherence and treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intravitreal InjectionsNeedlesRetinal DiseasesHumansRetrospective StudiesMaleAgedFemaleEquipment DesignCross-Over StudiesAngiogenesis InhibitorsMiddle AgedPain MeasurementBevacizumabRanibizumab

Stichwörter der Autor:innen

Eye painIntravitreal injectionsNeedlesVitreous body

Substanzen

Angiogenesis InhibitorsBevacizumabRanibizumab

Autor:innen und Institutionen

  • Department of Ophthalmology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.
  • Department of Ophthalmology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. yongsok.ji@jnu.ac.kr.

Zitieren

APA

Cho, Y. J., Kook, K. Y., Park, D. H., & Ji, Y. S. (2026). Effectiveness of Ultrathin 40-Gauge Needles for Intravitreal Injections. Korean Journal of Ophthalmology, 40(4), 341-347. https://doi.org/10.3341/kjo.2025.0134

Vancouver

Cho YJ, Kook KY, Park DH, Ji YS. Effectiveness of Ultrathin 40-Gauge Needles for Intravitreal Injections. Korean Journal of Ophthalmology. 2026;40(4):341-347. doi:10.3341/kjo.2025.0134

BibTeX
@article{Cho2026,
  author = {Cho, Ye Ji and Kook, Kyung Yun and Park, Do Hee and Ji, Yong-Sok},
  title = {Effectiveness of Ultrathin 40-Gauge Needles for Intravitreal Injections},
  journal = {Korean Journal of Ophthalmology},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {341--347},
  doi = {10.3341/kjo.2025.0134}
}
Kostenlos starten →